UCSF Chancellor Susan Desmond-Hellmann, MD, MPH, will be inducted today into the American Academy of Arts and Sciences, alongside some of the world's other most distinguished scholars, artists and institutional leaders.
Desmond-Hellmann, a renowned oncologist and biotechnology leader who now heads the nation's largest public biomedical research institution, was among five members of the 210 new fellows to address her colleagues, focusing on today's unprecedented opportunities to understand human biology and improve human health.
"I want to challenge us to set the bar high, to imagine what's possible, and then to make it happen," she said. "Patients are waiting. These patients and their families deserve our sense of urgency around using all of our scientific knowledge to allow each human being the best chance possible to live a full life without pain and suffering."
Desmond-Hellmann, who took the helm of UCSF in August 2009, has committed her career to expediting the translation of scientific research into life-saving therapies for patients. Trained at UCSF, Desmond-Hellmann spent several years in the early 1990s working as a community oncologist, where she became frustrated with the limited options available to cancer patients.
She went on to lead product development at Genentech Inc., the world's first biotechnology company, which became the nation's top producer of anti-cancer drug treatments during her tenure. As Genentech's president of product development, Desmond-Hellmann oversaw the launch of the cancer drugs Avastin, Herceptin and Rituxan, among others.
Desmond-Hellmann was named to the Biotech Hall of Fame in 2006, has appeared among Fortune's "Top 50 Most Powerful Women in Business," and was named by Forbes as one of the world's seven most powerful innovators and "a hero to legions of cancer patients."
In her role as UCSF chancellor, Desmond-Hellmann oversees a $3.3 billion organization that inclu
|Contact: Kristen Bole|
University of California -- San Francisco